Stiff person syndrome: 2026 so far

Small series highlighted pump benefits alongside meaningful procedure risks.

In the months covered, a 6-person multicenter report linked intrathecal baclofen pumps (a surgically placed device that delivers baclofen into spinal fluid) to large reductions in stiffness and spasms. It also reported better mobility or breathing. In people who were followed, benefits lasted about 2.5 to 4 years. One person had a serious postoperative infection (septic shock), which required temporary device removal. Case reports also continued to describe noticeable symptom improvement with GABA-acting medicines (drugs that boost the brain's main calming signal), such as clonazepam, sometimes with baclofen, in classic anti-GAD-positive SPS. Earlier in 2026, a single case also described an objective needle EMG change (a test that records muscle electrical activity) after an intravenous diazepam challenge that matched symptom change. Together, these reports add real-world examples of symptom-relief approaches, while also showing that invasive options can come with serious complications.

Research covered in: January 2026, August 2026

Case-level reports increasingly described sequential or combined immunotherapies.

In the months covered, multiple case reports and small series described improvement after immune-targeting treatments. Many reports used more than one therapy, which makes it hard to know which drug drove the benefit. Examples included improvement after IVIG (intravenous immunoglobulin, pooled antibodies given by vein), including a thymoma-associated case with fewer spasms and improved mobility. Another report described plasma exchange (a procedure that filters antibodies from blood) plus rituximab in a Graves disease overlap case. There were also reports of recovery in severe SPS spectrum illness after repeated IVIg in GlyR1 antibody-positive PERM (progressive encephalomyelitis with rigidity and myoclonus, a severe SPS-spectrum condition). Newer or less-established approaches appeared as case-level signals. One report described substantial improvement after efgartigimod followed by ofatumumab in anti-GAD65 SPS. A separate case described stable SPS during periodic efgartigimod given for overlapping myasthenia gravis (an autoimmune disease that causes muscle weakness). Overall, the published treatment experiences so far in 2026 were mostly individualized and small-scale, with variable response and limited ability to predict which specific immune therapy will help whom.

Research covered in: February 2026, March 2026, April 2026, May 2026, June 2026, July 2026, August 2026

Observational studies sharpened the picture of disability and survival.

Observational data in the months covered added longer-range context beyond short-term symptom changes. A long follow-up study of 54 people (median 9 years) reported that most were functionally independent by last follow-up. Even so, walking difficulty often persisted, and many still needed gait aids. Older age and needing bilateral gait assistance at the worst point were linked to poorer later function. Separately, a national registry study in Denmark reported that SPS diagnoses increased over time. It also found higher 10-year mortality in 30 people with SPS compared with 3,000 matched controls, without establishing why the risk was higher. These studies suggest that long-term trajectories can include meaningful gains in day-to-day independence, while ongoing mobility needs and broader health risks may still shape life with SPS.

Research covered in: May 2026, June 2026

Reports reinforced antibody-led workups and highlighted limits of single tests.

So far in 2026, case reports repeatedly described delayed or mistaken initial diagnoses. These included orthopedic pathways and functional or psychiatric mislabeling. Anti-GAD65 antibodies often served as a key clue when routine tests were unrevealing. Individual reports also showed how EMG (electromyography, a test that measures muscle electrical activity) could support diagnosis in specific situations. Examples included continuous motor unit activity in one case and a needle EMG response to an intravenous diazepam challenge in another. In contrast, a small clinical study (11 people with SPS plus comparison groups) found an exteroceptive reflex test using surface EMG (sensors on the skin that record muscle signals) did not clearly separate SPS from healthy controls or other neurologic conditions. In the months covered, diagnosis was still presented as context-dependent and often multi-step, with some tests helpful in select cases and others not reliably definitive on their own.

Research covered in: January 2026, February 2026, May 2026, June 2026, July 2026, August 2026

Evidence highlighted a cancer-linked antibody subgroup and rare ICU-level events.

In the months covered, reports repeatedly connected antibody subtype to different risks and monitoring needs. A pooled review of 64 anti-amphiphysin stiff-person spectrum disorder cases reported malignancy in 60 people. When timing was available, symptoms often started before the cancer was detected. Better functional outcomes were described when cancer treatment was included. Earlier small case-based reporting also noted lung cancer in one anti-amphiphysin-positive patient. Separately, a single September case report described intense spasms during attempted breathing-tube removal followed by low oxygen and cardiac arrest from dangerous rhythms. Cardiac MRI (a heart scan using magnetic imaging) suggested possible myocarditis (heart muscle inflammation), but this was not biopsy-confirmed, and an ICD (implantable cardioverter-defibrillator, a device that treats dangerous heart rhythms) was placed. These reports highlight that some antibody-defined SPS spectrum presentations may lead clinicians to consider cancer evaluation, and that rare severe complications can occur in high-stress medical settings even though frequency and predictors were not established.

Research covered in: April 2026, August 2026, September 2026